Calculated
DCF
Free cash flow, growth, discount rate, and terminal growth form an intrinsic value range.
27.49 USD25.70 USD32.22 USD
25.70 USDThis model is a limited scenario reference for this sector.
N
HealthcareDrug Manufacturers - GeneralDenmark
Novo Nordisk A/S (NVO) Valuation Assumptions
Review Novo Nordisk A/S (NVO) valuation assumptions across intrinsic value, DCF, reverse DCF implied growth, EV/EBITDA, P/FCF, and financial trends.
NYQ · US · USD
Latest price46.07 USD
30D+27.53%
Price vs model median+47.1%Model median is the median base output from applicable absolute models, excluding Reverse DCF.
Quick answer
What growth is the market currently pricing into NVO?
At 46.07 USD, TickerVal's reverse DCF setup implies roughly 5.7% annual FCF growth for 10 years for NVO, using the current normalized FCF base, a 9% discount rate, and 3.0% terminal growth. The rest of the page shows valuation assumptions, model differences, and source-data context for research reference.
What price implies
What does the current price imply?
At 46.07 USD, the model implies roughly 5.69% annual FCF growth for 10 years, with required long-term operating margin near 41.06% and terminal growth around 3%. This module is a research reference.
Implied FCF CAGR5.69%
10-year Reverse DCF scenario
Required long-term operating margin41.06%
Five-year median × 0.95
Implied terminal growth3%
From current model assumptions
Discount rate assumption9%
Estimated from current sector rules
Adjust assumptions+
Adjust assumptions
Move assumptions to see how the current price implied conditions change.
Forecast horizon10Y
Historical implied expectations
How does today's implied growth compare with history?
Calculated from selected historical prices and current normalized FCF assumptions, not a full point-in-time backtest.
Current implied FCF CAGR5.7%
5Y monthly median9.57%
Current vs 5Y median-3.87 pts
Showing 8 of 12 report price anchors
| Report price anchor | Price date | Anchor price | Implied FCF CAGR |
|---|---|---|---|
| Q1-2026 | 2026/03/31 | 36.75 USD | 2.73% |
| FY2025 | 2025/12/31 | 49.08 USD | 6.51% |
| Q4-2025 | 2025/12/31 | 49.08 USD | 6.51% |
| Q3-2025 | 2025/09/30 | 53.53 USD | 7.65% |
| Q2-2025 | 2025/06/30 | 65.84 USD | 10.35% |
| Q1-2025 | 2025/03/31 | 66.24 USD | 10.43% |
| FY2024 | 2024/12/31 | 80.75 USD | 13.03% |
| Q4-2024 | 2024/12/31 | 80.75 USD | 13.03% |
20264.55%
Avg 4.8% · Samples 5
20258.86%
Avg 8.97% · Samples 12
202417.79%
Avg 17.5% · Samples 12
202312.23%
Avg 12.7% · Samples 12
Historical valuation multiples
How have EV/EBITDA and P/FCF changed over the last 5 years?
Annual fiscal-period anchored: month-end prices are paired with the most recent annual fiscal period ending on or before each date, covering the last 5 years (41 monthly samples). Multiples are research references; financial-sector or otherwise non-comparable companies require sector-specific context.
P/E
Market cap divided by reported net income (annual fiscal-period snapshot).
12.72x
Below history · P9
Current5Y medianTypical range IQR
5Y median36.89x
Current12.72x · P9
5Y low 9.97xCurrent vs median-65.53%5Y high 54.84x
IQR 17.25–43.44x · 41 monthly samples
P/FCF
Market cap divided by reported free cash flow.
44.94x
Near median · P65
Current5Y medianTypical range IQR
5Y median39.07x
Current44.94x · P65
5Y low 20.62xCurrent vs median+15.01%5Y high 57.72x
IQR 31.94–47.48x · 41 monthly samples
EV/EBITDA
Enterprise value (market cap + debt − cash) divided by EBITDA.
8.98x
Below history · P9
Current5Y medianTypical range IQR
5Y median26.84x
Current8.98x · P9
5Y low 7.18xCurrent vs median-66.55%5Y high 39.82x
IQR 12.36–31.82x · 41 monthly samples
Month-end historical multiples
A date-friendly view for historical EV/EBITDA, P/FCF, and P/E queries.
Showing 8 of 41 month-end samples
| Month-end | Price | P/E | P/FCF | EV/EBITDA | Fiscal period used |
|---|---|---|---|---|---|
| 2026-05-08 | 46.07 USD | 12.72x | 44.94x | 8.98x | 2025-12-31 |
| 2026-04-30 | 42.22 USD | 11.66x | 41.18x | 8.28x | 2025-12-31 |
| 2026-03-31 | 36.75 USD | 10.15x | 35.85x | 7.3x | 2025-12-31 |
| 2026-02-27 | 36.13 USD | 9.97x | 35.24x | 7.18x | 2025-12-31 |
| 2026-01-30 | 57.33 USD | 15.83x | 55.92x | 11.01x | 2025-12-31 |
| 2025-12-31 | 49.08 USD | 13.55x | 47.88x | 9.52x | 2025-12-31 |
| 2025-11-28 | 47.60 USD | 15.08x | 21.86x | 10.88x | 2024-12-31 |
| 2025-10-31 | 47.71 USD | 15.11x | 21.91x | 10.9x | 2024-12-31 |
Valuation overview
How do the valuation assumptions fit together?
Novo Nordisk A/S (NVO) valuation on TickerVal is designed to help readers understand the operating expectations embedded in the current market price. At 46.07 USD, the page brings intrinsic value analysis, DCF outputs, reverse DCF implied growth, EV/EBITDA, P/FCF, and valuation assumptions into one research view within the Healthcare sector and the Drug Manufacturers - General industry. Instead of treating one model as a final answer, TickerVal compares cash-flow, earnings-power, balance-sheet, and relative-multiple lenses so the differences between models are visible. The reverse DCF view currently shows implied growth of 5.7%, while the model median reference sits at +47.1% versus the current price. The DCF and reverse DCF sections focus on free cash flow, discount rate, terminal growth, and the long-term growth path implied by the current price. EV/EBITDA and P/FCF provide additional context for capital structure and cash-flow multiples. The financial trends section connects those valuation assumptions back to reported revenue of 49B USD, free cash flow of 5B USD, margins, and balance-sheet facts from public filings. Readers can use the layout to compare assumptions across models before reviewing the underlying source data. This page is intended for transparent research reference, model review, and assumption checking.
Valuation model range vs. current price
Each row shows a model output range, with a vertical line for the current price.
DCFCalculated · Limited reference
25.70 USD-32.22 USD
Earnings Power ValueCalculated
31.31 USD-31.31 USD
Graham NumberCalculated · Limited reference
23.65 USD-23.65 USD
Owner EarningsCalculated
44.50 USD-93.81 USD
Current price reference line
Why do valuation models give different answers?
Different models rely on different financial facts. The status blocks show which lenses fit this page data.
| Model | Fit | Context |
|---|---|---|
| DCF | Limited | Latest FCF is an outlier, so DCF is a limited scenario reference. |
| Owner Earnings | Suitable | Useful when net income, D&A, and capex support owner-earnings scenarios. |
| Reverse DCF | Suitable | Shows the FCF growth implied by current price under stated assumptions. |
| Earnings Power Value | Suitable | Useful for mature operating profit, with limited emphasis on growth. |
| Graham Number | Limited | Works best when EPS and book value are both positive. |
| Dividend Discount Model | Not meaningful | Needs explicit dividend history, which is not included in the current version. |
| Net-Net Liquidation Value | Not meaningful | Requires current asset and liability detail beyond the current data set. |
| PEG | Limited | A quick growth multiple lens when EPS history is positive. |
| EV/EBITDA | Limited | Useful for capital structure context when operating profit is available. |
| P/FCF | Limited | A compact free-cash-flow multiple view for positive FCF years. |
| P/B | Limited | More useful for asset-heavy balance sheets than asset-light companies. |
| P/S | Limited | A revenue multiple lens when profit or FCF is not stable. |
| Peer Comparison | Not meaningful | Standardized peer comparisons are not included in the current version. |
Which valuation models are being calculated?
Hover each model row to inspect formulas and inputs.
Current price46.07 USD
Model median reference31.31 USD
Price vs model median+47.1%
Price date2026/05/08
31.31 USD31.31 USD31.31 USD
+47.14%
Calculated
Owner Earnings
Uses net income, D&A, and capex as an owner-earnings proxy.
44.50 USD72.00 USD93.81 USD
-36.01%
72.00 USDCurrent price is 36% below the base model value.Adjusted reference: 124.61 USD
Calculated
Reverse DCF
Solves the forward FCF growth rate implied by the current price.
Implied growth5.7%
Current price implies roughly 5.7% annualized FCF growth.
5.7%Current price implies roughly 5.7% annualized FCF growth.
Calculated
Earnings Power Value
Estimates earnings power value without assuming growth.
31.31 USD31.31 USD31.31 USD
+47.14%
31.31 USDCurrent price is 47.1% above the base model value.
Updated: 2026/05/10
Which financial trends support the assumptions?
Annual financial metrics with switchable views. · Unit: USD
FY2025 · Dec 2025 report12 records
Revenue49B USD
Net income16B USD
Free cash flow5B USD
CapEx-14B USD
Operating cash flow19B USD
Valuation basis and non-recurring items
Collapsed by default. Expand to inspect structured one-time items and adjusted figures without making them the primary page focus.
ExpandCollapse
Valuation basis and non-recurring items
Collapsed by default. Expand to inspect structured one-time items and adjusted figures without making them the primary page focus.
A positive amountAfterTax means the item increased reported net income; a negative value means it reduced reported net income. Adjusted net income = reported net income minus total after-tax impact. Valuation defaults to reported figures; adjusted figures are shown to observe one-time-item impact.
| Period | Item | Category | After-tax impact | Confidence |
|---|---|---|---|---|
| 2025/12/31 | Asset sale gain/loss | Asset sale gain/loss | 755M USD | Medium |
| 2024/12/31 | Asset sale gain/loss | Asset sale gain/loss | -115M USD | Medium |
| 2023/12/31 | Asset sale gain/loss | Asset sale gain/loss | 198M USD | Medium |
| 2022/12/31 | Asset sale gain/loss | Asset sale gain/loss | -593M USD | Medium |
Ad placement
Which reported financials feed the models?
Financial DetailsShowing latest 5 / 12
| Period | Type | Revenue | Net Income | Adjusted net income | Free Cash Flow | Diluted EPS | Adjusted EPS |
|---|---|---|---|---|---|---|---|
| 2025/12/31 | Annual | 49B USD | 16B USD | 15B USD | 5B USD | 3.62 | 3.45 |
| 2024/12/31 | Annual | 41B USD | 14B USD | 14B USD | 10B USD | 3.16 | 3.18 |
| 2023/12/31 | Annual | 34B USD | 12B USD | 12B USD | 10B USD | 2.76 | 2.72 |
| 2022/12/31 | Annual | 25B USD | 8B USD | 9B USD | 9B USD | 1.75 | 1.88 |
| 2021/12/31 | Annual | - | - | - | - | - | - |
Where does this data come from?
Open to inspect field-level SEC EDGAR source, filing form, and derived notes.
SEC EDGAR
Where does this data come from?
Open to inspect field-level SEC EDGAR source, filing form, and derived notes.
Frequently asked questions
Quick notes on price-implied expectations, model differences, and source data.
What is Novo Nordisk A/S's intrinsic value?
Novo Nordisk A/S's intrinsic value on TickerVal is reviewed through DCF outputs, reverse DCF implied growth, EV/EBITDA, P/FCF, valuation assumptions, and financial trends from public filings.
How is NVO valued on TickerVal?
TickerVal values NVO by comparing intrinsic value models, DCF and reverse DCF assumptions, cash-flow multiples, earnings-power references, and reported financial trends.
What does the current stock price imply?
The reverse DCF view estimates the free-cash-flow growth path implied by the current stock price under stated discount-rate and terminal-growth assumptions.
Which valuation models are used?
TickerVal uses DCF, reverse DCF, Owner Earnings, EPV, Graham Number, EV/EBITDA, P/FCF, P/B, P/S, and other model references where the underlying data is available.
Is this investment advice?
No. TickerVal does not provide investment advice, ratings, price targets, or buy/sell recommendations.
Early supporter list
Get notified as TickerVal adds saved assumptions.
Join the research reference list for product updates, model notes, and transparent assumption workflows.
Ad placement